. This cohort included 64 PCD, 79 metastases, and 195 non-PCD cases. Valid GPS results were obtained for 259 men (93%). In univariable analysis GPS was strongly associated with PCD -HR/20 GPS units ¼ 3.23 (p <0.001), and metastasis -HR/20 units ¼ 2.75 (p <0.001). The association between GPS and both endpoints remained significant in multivariable analysis after adjusting for NCCN: 1) PCD: HR/20 units ¼ 2.69; 2) metastasis: HR/ 20 units ¼ 2.34 (p<0.001 for each). GPS was also significantly associated with both endpoints adjusting for AUA and CAPRA with similar HR (p<0.001 for each). No patient with low or intermediate risk disease and a GPS result < 20 developed metastases or PCD.
INTRODUCTION AND OBJECTIVES:
Although prostate atrophy (PA) is a common histological finding in prostate biopsy specimens its clinical significance remains unclear. Recent data suggests that PA in a prostate biopsy negative for prostate cancer (PCa) confers a decreased risk of subsequent PCa detection. However, the extent of PA varies from patient to patient. Therefore, we sought to evaluate whether baseline PA extent is associated with PCa incidence at 2-year repeat prostate biopsy in a clinical trial with systematic biopsies.
METHODS: We performed a retrospective analysis of 3,165 men 50-75 years-old with prostate-specific antigen (PSA) between 2.5-10ng/mL and a prior negative biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events (REDUCE) trial who underwent a 2-year repeat biopsy after a negative baseline biopsy for PCa. PA extent was defined as the percentage of cores with atrophic changes. The association of baseline PA with positive 2-year biopsies was evaluated with logistic regression in uni-and multivariable analysis, controlling for baseline covariates.
RESULTS: PA involving none, 1-25%, 26-50%, 51-75% and >75% of the baseline cores was observed in 966 (30.5%), 1189 (37.6%), 677 (21.4%), 209 (6.6%), 124 (3.9%) cases, respectively. More extensive PA was associated with older age, lower prostatespecific antigen, larger prostate volume and higher prevalence of acute and chronic inflammations (all P<0.05). Compared to subjects without PA, those with 1-25%, 26-50%, 51-75% and >75% core involvement had an odds-ratio for PCa of 0.65 (95%CI¼0.52-0.81), 0.60 (95% CI¼0.46-0.78), 0.56 (95%CI¼0.37-0.86) and 0.35 (95%CI¼0.19-0.67), respectively (Table) . In multivariable analysis, the extent of PA was independently associated with lower PCa risk (P<0.001). More extensive PA was associated with lower incidence of both low-(Gleason 2-6) and high-grade (Gleason 7-10) PCa (both P<0.01).
CONCLUSIONS: In a cohort of men undergoing repeat prostate biopsy 2 year after a negative baseline biopsy for PCa, the extent of baseline PA is independently associated with lower PCa risk in a dosedependent fashion. is a common histological finding in prostate biopsy specimens. It is known to mimic prostate cancer (PCa) on imaging and histology. Recent data suggest PA in a negative biopsy is associated with lower risk of PCa detection in subsequent biopsies, and lower risk of high-grade PCa in men who are eventually diagnosed with PCa. However, the association of PA in prostate biopsies with PCa grade in radical prostatectomy (RP) specimens has not been studied in earnest. Therefore, the objective of this study is to evaluate whether the presence of PA in a baseline prostate biopsies negative for PCa is associated with PCa grade in the surgical specimen among patients eventually diagnosed with PCa undergoing RP.
METHODS: We performed a retrospective analysis of 137 men, 50-75 years old with prostate-specific antigen (PSA) between 2.5-10 ng/ ml and a prior negative biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events (REDUCE) trial, who were diagnosed with PCa in a prostate biopsy and underwent RP during the study interval. All biopsy slides were read central and systematically graded for PA was defined as absent or present. PCa grade was defined as low-grade (Gleason 2-6) or high-grade (Gleason 7-10). The association of baseline PA with PCa grade in the surgical specimen was evaluated with logistic regression in uni-and multivariable analysis, controlling for baseline patient characteristics.
RESULTS: Among 137 men diagnosed with PC who underwent an RP in REDUCE, 64 (46.7%) had PA in the baseline prostate biopsy. The presence of PA was not associated with baseline patient characteristics (age, body-mass index, PSA levels, prostate volume, race, family history of PCa or digital rectal exam, all P>0.05, Table) . The presence of baseline PA was associated with lower risk of high-grade PCa (OR¼0.40, 95%CI¼0.20-0.80, P¼0.010) in the surgical specimen. Results were unchanged in multivariable analysis (OR¼0.46, 95% CI¼0.22-0.96, P¼0.039).
CONCLUSIONS: In a cohort of men with negative baseline biopsy who were eventually found to have PCa in a repeat prostate biopsy and underwent RP, the presence of baseline PA was independently associated with lower risk of high-grade PCa in the surgical specimen. PA seems to be associated with lower PCa risk and aggressiveness.
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